Docking, synthesis and cytotoxic test on Human Breast Cancer cell line T47D of N-(phenylcarbomothyoil)-benzamide

• Main Authors: Kesuma, Dini, Siswandono, Siswandono, Purwanto, Bambang Tri, Rudyanto, Marcellino
• Format: Article PeerReviewed
• Language: English; English
• Published: School of Pharmacy, People'e University 2018
• Subjects: R Medicine; RS Pharmacy and materia medica; RS1-441 Pharmacy and materia medica; RS200-201 Pharmaceutical dosage forms
• Online Access: http://repository.unair.ac.id/77466/2/C-9.pdf; http://repository.unair.ac.id/77466/3/Validasi%20dan%20Reviewer%20C-9.pdf; http://repository.unair.ac.id/77466/; http://www.wjpr.net/dashboard/abstract_id/9566
• Institution: Universitas Airlangga

Introduction: New breast anticancer compound N- (phenylcarbamothioyl)-benzamide have been synthesized, initiated with molecular modeling in silico which is docking between test compounds with SIRT-1 receptor PDB code: 4I5I to predict the bonding of test compounds with receptors. Methods: The compounds are synthesized from benzoyl chloride reaction with N-phenylthiourea. The molecular structure is confirmed using FTIR, 1H-NMR, 13C-NMR and Mass Spectra. Anticancer activity is tested in vitro against human breast cancer cells (T47D) using an MTT assay. Result: RS (Rerank Score) value and anticancer activity of test compound obtained are higher than Hydroxyurea as the reference compound. The Value of IC50 N-(phenylcarbamothioyl)-benzamide is 0.53 mM (T47D cell) and 49.40 mM (Vero cel) and also IC50 Hydroxyurea is 4.58 mM (T47D cells). It is predicted that the mechanism of action of these new compounds is targeted cell because it has toxic effect on cancer cells and is not toxic in normal Vero cells. Conclusion: This new compound are highly potential as an anticancer agent against the human breast carcinoma cell line (T47D).